Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Common Equity (2016 - 2025)

Neurocrine Biosciences' Common Equity history spans 16 years, with the latest figure at $3.3 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 25.62% year-over-year to $3.3 billion; the TTM value through Dec 2025 reached $3.3 billion, up 25.62%, while the annual FY2025 figure was $3.3 billion, 25.62% up from the prior year.
  • Common Equity reached $3.3 billion in Q4 2025 per NBIX's latest filing, up from $3.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $3.3 billion in Q4 2025 to a low of $1.2 billion in Q1 2021.
  • Average Common Equity over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 72.15% in 2021, then increased 6.27% in 2025.
  • A 5-year view of Common Equity shows it stood at $1.4 billion in 2021, then rose by 24.29% to $1.7 billion in 2022, then soared by 30.69% to $2.2 billion in 2023, then grew by 16.03% to $2.6 billion in 2024, then rose by 25.62% to $3.3 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Common Equity are $3.3 billion (Q4 2025), $3.0 billion (Q3 2025), and $2.7 billion (Q2 2025).